Black Titan (NASDAQ:BTTC – Get Free Report) and Cycurion (NASDAQ:CYCU – Get Free Report) are both small-cap technology companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.
Insider & Institutional Ownership
6.6% of Cycurion shares are held by institutional investors. 53.7% of Black Titan shares are held by company insiders. Comparatively, 4.6% of Cycurion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and recommmendations for Black Titan and Cycurion, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
| Cycurion | 1 | 1 | 1 | 0 | 2.00 |
Cycurion has a consensus target price of $56.00, suggesting a potential upside of 2,492.59%. Given Cycurion’s stronger consensus rating and higher probable upside, analysts plainly believe Cycurion is more favorable than Black Titan.
Valuation & Earnings
This table compares Black Titan and Cycurion”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Black Titan | $180,000.00 | 21.93 | -$4.71 million | ($2.95) | -0.12 |
| Cycurion | $15.13 million | 0.46 | -$23.67 million | ($24.64) | -0.09 |
Black Titan has higher earnings, but lower revenue than Cycurion. Black Titan is trading at a lower price-to-earnings ratio than Cycurion, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Black Titan has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Cycurion has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
Profitability
This table compares Black Titan and Cycurion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Titan | N/A | N/A | N/A |
| Cycurion | -98.83% | -98.55% | -46.19% |
Summary
Black Titan beats Cycurion on 8 of the 13 factors compared between the two stocks.
About Black Titan
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
About Cycurion
Cycurion is a global leading provider of Network Communications and Information Technology Security Solutions. Our mission is to develop and deliver world-class, cutting-edge solutions for our clients, regardless of size or complication, expressly optimizing your IT environment to meet the business need and to keep projects on track and on budget.
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
